2023-04-21

Guangdong releases the "Opinions on Promoting High-Quality Development of Health and Wellness," aiming to foster a stem cell industry cluster in the Guangdong-Hong Kong-Macao Greater Bay Area.

Promote collaborative innovation in the biopharmaceutical sector. Support hospitals within the province to strengthen partnerships with healthcare providers from Hong Kong and Macao, expanding the implementation of the "Hong Kong and Macao Pharmaceuticals and Medical Devices Facilitation" policy. Encourage the development of high-end health management institutions and medical tourism/healthcare facilities. Additionally, support streamlined registration and approval processes for traditional Chinese medicines already approved for sale in Hong Kong and Macao. Finally, foster the growth of a stem-cell industry cluster in the Guangdong-Hong Kong-Macao Greater Bay Area.

2023-04-12

Jiuzhitang Maker attends the Stem Cell Summit Workshop

As a leading force in the field of clinical stem cell research and a member organization of the China Association for Medical Biotechnology, Dr. Gao Yansong, General Manager of Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as "Jiuzhitang Maker"), was invited to attend this prestigious event. There, he joined key officials responsible for stem cell clinical research management across the country, along with renowned experts in the field, as well as representatives from stem cell clinical research institutions, stem cell product development firms, and financial and investment organizations, to collectively learn from and discuss the latest advancements in China’s stem cell clinical research achievements.

2023-03-24

Central Office of the CPC and the General Office of the State Council: Strengthen cutting-edge medical technologies such as stem cells, regenerative medicine, and biotherapy.

Recently, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the "Opinions on Further Improving the Medical and Healthcare Service System." The opinions emphasize strengthening the development and capacity-building of clinical medicine, public health, and medical device R&D systems, while also advancing cutting-edge medical technologies such as genomics, stem cell and regenerative medicine, next-generation vaccines, biotherapies, and precision medicine.

2023-03-21

Stem Cell Science Comic | The Fourth Medical Technology Revolution (Original)

Original science popularization article on stem cells!

2023-03-16

Jiuzhitang Maker's clinical-grade stem cell preparation passes multiple prestigious certifications.

Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as "Jiuzhitang Maker"), a national high-tech enterprise specializing in the production of clinical-grade stem cells that meet both Chinese and U.S. pharmaceutical regulatory requirements, has consistently upheld the time-honored principle of Jiuzhi堂: "A healer should exert every effort, and a pharmacist should act with integrity." As a result, quality has always been prioritized as the cornerstone of Jiuzhitang Maker's development, enabling the company to achieve a series of remarkable accomplishments.

2023-03-10

National Committee of the Chinese People's Political Consultative Conference member Li Guohua proposed incorporating stem-cell drug research and development into the national strategy, along with formulating a national development plan.

Establish a national-level stem cell research center focused on foundational studies, and build several national-level clinical research centers dedicated to stem cell medicine. These initiatives will attract top-tier basic and clinical scientists to collaborate on developing stem cell-based products aimed at treating common, challenging, and rare diseases. Additionally, create a national platform for trading stem cell-related scientific advancements, providing critical support to transform groundbreaking research outcomes into market-ready products.

2023-03-09

Shandong Free Trade Zone, Jinan Area: Clinical Translation of Stem Cell Therapy and Other Innovations to Proceed Under Controllable Risk Conditions

The plan explicitly states: supporting multi-center clinical trials for biopharmaceutical products such as gene therapy and cell therapy, and implementing mutual recognition of ethical review outcomes. It also calls for exploring the development of relevant standard systems to pilot clinical translation applications—such as stem cell therapy and bioartificial liver treatments—in a manner that ensures risks remain under control.

2023-02-27

People's Daily: Cell Therapy Industry Holds Significant Growth Potential

Cell therapy is regarded as a niche yet innovative area within the pharmaceutical R&D landscape. Over the past two years, relevant regulatory authorities have issued multiple guidance documents specifically tailored to cell therapy products, helping to streamline the review and approval process. Domestically, clear guidelines have been established at every stage—from product application to manufacturing—supporting the development of cell therapy innovations. Meanwhile, local governments continue to introduce policies aimed at fostering and encouraging the research, development, and commercialization of cell therapy products.

2023-02-17

Jiuzhitang Maker Receives ISO Triple-Certification Recognition

Recently, Jiuzhitang Maker officially received the prestigious ISO 9001, ISO 14001, and ISO 45001 international certifications from a leading accreditation body. This recognition fully acknowledges Jiuzhitang Maker's years of dedication to establishing robust, professional, and standardized practices in stem-cell drug R&D quality management, environmental management, and occupational health and safety management.